Clinical management of typical and atypical carcinoids/neuroendocrine tumors in ENETS centres of excellence (CoE): Survey from the ENETS lung NET task force.
ENETS
adjuvant treatment
lung carcinoid
neuroendocrine tumour
survey
Journal
Journal of neuroendocrinology
ISSN: 1365-2826
Titre abrégé: J Neuroendocrinol
Pays: United States
ID NLM: 8913461
Informations de publication
Date de publication:
16 May 2024
16 May 2024
Historique:
revised:
27
03
2024
received:
02
01
2024
accepted:
05
05
2024
medline:
17
5
2024
pubmed:
17
5
2024
entrez:
16
5
2024
Statut:
aheadofprint
Résumé
Lung carcinoid tumours are neuroendocrine neoplasms originating from the bronchopulmonary tract's neuroendocrine cells, accounting for only 1%-3% of all lung cancers but 30% of all neuroendocrine tumours. The incidence of lung carcinoids, both typical and atypical, has been increasing over the years due to improved diagnostic methods and increased awareness among clinicians and pathologists. The most recent WHO classification includes a subgroup of lung carcinoids with atypical morphology and higher mitotic count and/or Ki67 labelling index. Despite appropriate surgery, the 5-year survival rate for atypical carcinoids barely exceeds 50%-70%. The role of adjuvant therapy in lung carcinoids is not well-defined, and clinical decisions are generally based on the presence of high-risk features. Long-term follow-up is essential to monitor for recurrence, although the optimal follow-up protocol remains unclear. To address the lack of consensus in clinical management decisions, the European Neuroendocrine Tumor Society (ENETS) initiated a survey among 20 expert centres. The survey identified varied opinions on approaches to imaging, surgery, use of adjuvant therapy, and follow-up protocols. Notably, the absence of dedicated multidisciplinary lung neuroendocrine tumour boards in some centres was evident. Experts agreed on the need for a prospective adjuvant trial in high-risk patients, emphasizing the feasibility of such a study. In conclusion, the study highlights the need for a more uniform adoption of existing guidelines in the management of lung carcinoid tumours and emphasizes the importance of international collaboration to advance research and patient care. Close collaboration between healthcare providers and patients is vital for effective long-term surveillance and management of these rare tumours.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13412Informations de copyright
© 2024 British Society for Neuroendocrinology.
Références
Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335‐1342.
Shah S, Gosain R, Groman A, et al. Incidence and survival outcomes in patients with lung neuroendocrine neoplasms in the United States. Cancers. 2021;13(8):1753.
Broder MS, Cai B, Chang E, Neary MP. Incidence and prevalence of neuroendocrine tumors of the lung: analysis of a US commercial insurance claims database. BMC Pulm Med. 2018;18(1):135.
Huguet I, Grossman AB, O'Toole D. Changes in the epidemiology of neuroendocrine tumours. Neuroendocrinology. 2017;104(2):105‐111.
Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063‐3072.
Rindi G, Mete O, Uccella S, et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr Pathol. 2022;33(1):115‐154.
Bischoff P, Trinks A, Wiederspahn J, et al. The single‐cell transcriptional landscape of lung carcinoid tumors. Int J Cancer. 2022;150(12):2058‐2071.
Fernandez‐Cuesta L, Foll M. Molecular studies of lung neuroendocrine neoplasms uncover new concepts and entities. Transl Lung Cancer Res. 2019;8(Suppl 4):S430‐S434.
Derks JL, Rijnsburger N, Hermans BCM, et al. Clinical‐pathologic challenges in the classification of pulmonary neuroendocrine neoplasms and targets on the horizon for future clinical practice. J Thorac Oncol. 2021;16(10):1632‐1646.
Araujo‐Castro M, Pascual‐Corrales E, Molina‐Cerrillo J, Moreno Mata N, Alonso‐Gordoa T. Bronchial carcinoids: from molecular background to treatment approach. Cancers. 2022;14(3):520.
Rekhtman N. Lung neuroendocrine neoplasms: recent progress and persistent challenges. Mod Pathol. 2022;35(Suppl 1):36‐50.
Koehler K, Iams WT. Carcinoid tumors outside the abdomen. Cancer Med. 2023;12(7):7893‐7903.
Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging. 2003;30(5):781‐793.
Al‐Toubah T, Montilla‐Soler J, El‐Haddad G, Haider M, Strosberg J. Somatostatin receptor expression in lung neuroendocrine tumors: an analysis of DOTATATE PET scans. J Nucl Med. 2023;64:1895‐1898.
Oberg K, Hellman P, Ferolla P, Papotti M, Group EGW. Neuroendocrine bronchial and thymic tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow‐up. Ann Oncol. 2012;23(Suppl 7):vii120‐vii123.
Baudin E, Caplin M, Garcia‐Carbonero R, et al. Lung and thymic carcinoids: ESMO clinical practice guidelines for diagnosis, treatment and follow‐up(☆). Ann Oncol. 2021;32(4):439‐451.
Edwards JG, Chansky K, Van Schil P, et al. The IASLC lung cancer staging project: analysis of resection margin status and proposals for residual tumor descriptors for non‐small cell lung cancer. J Thorac Oncol. 2020;15(3):344‐359.
Altorki N, Wang X, Kozono D, et al. Lobar or sublobar resection for peripheral stage IA non‐small‐cell lung cancer. N Engl J Med. 2023;388(6):489‐498.
Saji H, Okada M, Tsuboi M, et al. Segmentectomy versus lobectomy in small‐sized peripheral non‐small‐cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open‐label, phase 3, randomised, controlled, non‐inferiority trial. Lancet. 2022;399(10335):1607‐1617.
del Calvo H, Nguyen DT, Chan EY, Chihara R, Graviss EA, Kim MP. Anatomic pulmonary resection is associated with improved survival in typical carcinoid lung tumor patients. J Surg Res. 2022;275:352‐360.
Brown LM, Cooke DT, Jett JR, David EA. Extent of resection and lymph node assessment for clinical stage T1aN0M0 typical carcinoid tumors. Ann Thorac Surg. 2018;105(1):207‐213.
Pathipati MP, Yohannan TK, Tian L, et al. Examination of factors associated with lymph node metastases in lung carcinoids: results from a single institution retrospective cohort study. Lung Cancer. 2021;154:186‐194.
Martini N, Zaman MB, Bains MS, et al. Treatment and prognosis in bronchial carcinoids involving regional lymph nodes. J Thorac Cardiovasc Surg. 1994;107(1):1‐6. discussion 6–7.
Soldath P, Petersen RH. The surgical management of lung neuroendocrine neoplasms. Cancers. 2023;15(6):1695.
Anderson KL Jr, Mulvihill MS, Speicher PJ, et al. Adjuvant chemotherapy does not confer superior survival in patients with atypical carcinoid tumors. Ann Thorac Surg. 2017;104(4):1221‐1230.
Nussbaum DP, Speicher PJ, Gulack BC, et al. Defining the role of adjuvant chemotherapy after lobectomy for typical bronchopulmonary carcinoid tumors. Ann Thorac Surg. 2015;99(2):428‐434.
Gosain R, Mukherjee S, Yendamuri SS, Iyer R. Management of typical and atypical pulmonary carcinoids based on different established guidelines. Cancers. 2018;10(12):510.
Singh S, Bergsland EK, Card CM, et al. Commonwealth neuroendocrine tumour research collaboration and the north American neuroendocrine tumor society guidelines for the diagnosis and management of patients with lung neuroendocrine tumors: an international collaborative endorsement and update of the 2015 European neuroendocrine tumor society expert consensus guidelines. J Thorac Oncol. 2020;15(10):1577‐1598.
de Herder WW, Mazzaferro V, Tavecchio L, Wiedenmann B. Multidisciplinary approach for the treatment of neuroendocrine tumors. Tumori. 2010;96(5):833‐846.
Morin C, Benedetto KM, Deville A, et al. Management of neuroendocrine neoplasms: conformity with guidelines in and outside a center of excellence. Endocr Connect. 2022;11(6):e220097.
Magi L, Mazzuca F, Rinzivillo M, et al. Multidisciplinary management of neuroendocrine neoplasia: a real‐world experience from a referral center. J Clin Med. 2019;8(6):910.
Prasad V, Steffen IG, Pavel M, et al. Somatostatin receptor PET/CT in restaging of typical and atypical lung carcinoids. EJNMMI Res. 2015;5(1):53.
Maxwell JE, Howe JR. Imaging in neuroendocrine tumors: an update for the clinician. Int J Endocr Oncologia. 2015;2(2):159‐168.
Prasad V, Ambrosini V, Hommann M, Hoersch D, Fanti S, Baum RP. Detection of unknown primary neuroendocrine tumours (CUP‐NET) using (68)Ga‐DOTA‐NOC receptor PET/CT. Eur J Nucl Med Mol Imaging. 2010;37(1):67‐77.
Bhosale P, Shah A, Wei W, et al. Carcinoid tumours: predicting the location of the primary neoplasm based on the sites of metastases. Eur Radiol. 2013;23(2):400‐407.
Kayani I, Conry BG, Groves AM, et al. A comparison of 68Ga‐DOTATATE and 18F‐FDG PET/CT in pulmonary neuroendocrine tumors. J Nucl Med. 2009;50(12):1927‐1932.
Deleu AL, Laenen A, Decaluwe H, et al. Value of [(68)Ga]Ga‐somatostatin receptor PET/CT in the grading of pulmonary neuroendocrine (carcinoid) tumours and the detection of disseminated disease: single‐centre pathology‐based analysis and review of the literature. EJNMMI Res. 2022;12(1):28.
Jiang Y, Hou G, Cheng W. The utility of 18F‐FDG and 68Ga‐DOTA‐peptide PET/CT in the evaluation of primary pulmonary carcinoid: a systematic review and meta‐analysis. Medicine. 2019;98(10):e14769.
Filosso PL, Guerrera F, Falco NR, et al. Anatomical resections are superior to wedge resections for overall survival in patients with stage 1 typical carcinoids. Eur J Cardiothorac Surg. 2019;55(2):273‐279.
Girelli L, Casiraghi M, Sandri A, et al. Results of surgical resection of locally advanced pulmonary neuroendocrine tumors. Ann Thorac Surg. 2021;112(2):405‐414.
Chong CR, Wirth LJ, Nishino M, et al. Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors. Lung Cancer. 2014;86(2):241‐246.
Wirth LJ, Carter MR, Janne PA, Johnson BE. Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy. Lung Cancer. 2004;44(2):213‐220.
Walters SL, Canavan ME, Salazar MC, et al. A National study of surgically managed atypical pulmonary carcinoid tumors. Ann Thorac Surg. 2021;112(3):921‐927.
Ferguson MK, Landreneau RJ, Hazelrigg SR, et al. Long‐term outcome after resection for bronchial carcinoid tumors. Eur J Cardiothorac Surg. 2000;18(2):156‐161.
Lou F, Sarkaria I, Pietanza C, et al. Recurrence of pulmonary carcinoid tumors after resection: implications for postoperative surveillance. Ann Thorac Surg. 2013;96(4):1156‐1162.
Althubaiti A. Information bias in health research: definition, pitfalls, and adjustment methods. J Multidiscip Healthc. 2016;9:211‐217.